Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Sponsor
Asan Medical Center
Study ID
NCT00637091
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to investigate the response rate of cetuximab plus irinotecan every 2 weeks in patients harboring wild-type KRAS with and without detectable EGFR-expressing metastatic CRC after failure to irinotecan in an exploratory manner.

Key Dates

Start date
Mar 31, 2008
Status verified
Jan 2021
Primary completion
Sep 30, 2009
Completion
Sep 30, 2011

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: EGFR expression
    Patients' accrual will be adjusted by EGFR expression (positive vs. negative)

Primary Outcome Measure

Response rate [ Time Frame: 8 week ]

Related Studies